James Mitchum Net Worth

The estimated Net Worth of James P. Mitchum is at least $69.9 Thousand dollars as of 2 February 2016. Mr. Mitchum owns over 19,000 units of Tenax Therapeutics Inc stock worth over $69,920 and over the last 9 years he sold TENX stock worth over $0. In addition, he makes $0 as Director at Tenax Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Mitchum TENX stock SEC Form 4 insiders trading

James has made over 1 trades of the Tenax Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 19,000 units of TENX stock worth $50,540 on 2 February 2016.

The largest trade he's ever made was buying 19,000 units of Tenax Therapeutics Inc stock on 2 February 2016 worth over $50,540. On average, James trades about 3,800 units every 0 days since 2016. As of 2 February 2016 he still owns at least 19,000 units of Tenax Therapeutics Inc stock.

You can see the complete history of Mr. Mitchum stock trades at the bottom of the page.

James Mitchum biography

James Mitchum is a Director of the Company. Mr. Mitchum was recommended to the Corporate Governance and Nominating Committee for consideration as a director nominee by management. Mr. Mitchum has served as the Chief Executive Officer of Heart to Heart International a non-profit humanitarian organization since September 2014. From 2009 to July 2012, Mr. Mitchum served as President of the Americas for EUSA Pharma (USA), Inc., where he oversaw the streamlining of that business as well as the development, FDA approval and successful launch of a pediatric oncology drug in 2011. From 2005 to 2008, Mr. Mitchum served as President and Chief Executive Officer of Enturia, Inc., a privately owned drug-device company, based in Kansas City. From 2003 to 2005, Mr. Mitchum served as the President and Chief Executive Officer of Sanofi-Aventis Group Japan and was Chief Executive for Aventis Pharma UK from 2000 through 2002. He served in many senior financial roles from 1985 until 1999 with Hoechst Marion Roussel (HMR) and predecessor companies and was the Corporate Controller for HMR from 1997 until 2000. Mr. Mitchum currently serves as a director for NephroGenex Inc., a company developing drugs to treat kidney disease, and is a member of its Compensation Committee and chair of its Audit Committee. Mr Mitchum has also served as a director on numerous private company and organization boards. Mr. Mitchum earned an MBA in Business from the University of Tennessee in Knoxville, Tennessee and a Bachelor of Science degree in Business and Math from Milligan College in Johnson City, Tennessee.

How old is James Mitchum?

James Mitchum is 62, he's been the Director of Tenax Therapeutics Inc since . There are 6 older and 9 younger executives at Tenax Therapeutics Inc. The oldest executive at Tenax Therapeutics Inc is Ronald Blanck, 75, who is the Independent Chairman of the Board.

What's James Mitchum's mailing address?

James's mailing address filed with the SEC is C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE, NC, 27560.

Insiders trading at Tenax Therapeutics Inc

Over the last 10 years, insiders at Tenax Therapeutics Inc have traded over $5,051 worth of Tenax Therapeutics Inc stock and bought 571,282 units worth $853,236 . The most active insiders traders include Capital, Llc Armistice Capi..., Declan Doogan, and Stuart Rich. On average, Tenax Therapeutics Inc executives and independent directors trade stock every 218 days with the average trade being worth of $1,664,103. The most recent stock trade was executed by Gerald T Proehl on 8 August 2024, trading 1,666 units of TENX stock currently worth $6,131.

What does Tenax Therapeutics Inc do?

tenax therapeutics is focused on developing and commercializing pharmaceutical products that improve outcomes for patients who require treatment for various critical care conditions. our development portfolio includes novel product candidates that have the potential to address various critical care conditions with high unmet medical need.

Complete history of Mr. Mitchum stock trades at Tenax Therapeutics Inc

Tenax Therapeutics Inc executives and stock owners

Tenax Therapeutics Inc executives and other stock owners filed with the SEC include:

• Michael B. Jebsen CPA,
  Advisor
• Anthony A. DiTonno,
  CEO & Director
• Michael Jebsen,
  President, Chief Financial Officer
• Michael B. Jebsen,
  Pres & CFO
• Christopher T. Giordano,
  CEO, Pres & Director
• Ellen Corliss,
  Vice President, Corporate Communications & Investor Relations
• Chris Rallis,
  Independent Director
• Gregory Pepin,
  Independent Director
• Gerald Proehl,
  Director
• James Mitchum,
  Director
• Keith Maher,
  Director
• Steven Boyd,
  Director
• Paula Bokesch,
  Chief Medical Officer
• Doug Randall,
  Executive Vice President - Business and Commercial Operations
• Douglas Hay,
  Executive Vice President - Regulatory Affairs
• Anthony DiTonno,
  Chief Executive Officer, Director
• Ronald Blanck,
  Independent Chairman of the Board
• Eliot M. Lurier CPA,
  Interim Chief Financial Officer
• Dr. Stuart Rich M.D.,
  Chairman of Scientific Advisory Board, Chief Medical Officer & Director
• Nancy J. M. Hecox,
  Exec. VP of Legal Affairs, Gen. Counsel & Corp. Sec.
• John P Kelley,
  Chief Executive Officer
• Michael H. Davidson,
  
• Declan Doogan,
  
• Stuart Rich,
  Chief Medical Officer
• June Sherie Almenoff,
  
• Robyn Hunter,
  
• Christopher Thomas Giordano,
  CEO